Badran Elshenawy

The tumour microenvironment is a powerful promoter of multi-step tumorigenesis. Hypoxia is a strong driver for aggressive tumorigenesis and a significant contributor to intra-tumoral heterogeneity, which is commonly associated with poor patient prognosis and survival as well as therapeutic resistance. Cancer cells adapt to hypoxia through various mechanisms, metabolic rewiring being the mechanism of interest. My project uses single-cell RNA-Seq and CRISPR-Cas9 screens to characterise intra-tumoral of the hypoxic response and identify critical metabolic pathways contributing to hypoxia-driven, metabolic rewiring of cancer cells.

I graduated from the University of Bristol in 2020 with an MSci in Pharmacology. I carried out my Master’s research in the Neuroscience R&D department of Janssen Pharmaceutica NV, Belgium. My work was focused on the development of SOPs for the CatWalk gait analysis system and its subsequent development as a functional measure of therapeutic response in rodent models of neurodegenerative diseases.